In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.

We use cookies to optimise the design of this website and make continuous improvement. By continuing your visit, you consent to the use of cookies. Learn more

JUPITER: Randomized evidence on Rosuvastatin for primary prevention in individuals 70 years of age or older

Clinical Trial Update II


Presenter | see Discussant report

Robert Glynn, (United States of America)

Presentation webcast

Presentation slides

List of Authors:
Robert J Glynn and Paul M Ridker on behalf of the JUPITER Trial Study Group


Relationships of cholesterol levels with cardiovascular risk weaken with advancing age, and use of statins for primary prevention in older people remains controversial.

Among the 17802 apparently healthy men and women randomized in the JUPITER trial, 5695 were initially age 70 years or older. The trial was stopped after a median follow-up of 1.9 years (maximum, 5.0) on the basis of convincing evidence of efficacy with respect to the combined primary end point. We present here the observed effects of rosuvastatin in participants age 70 years or older, based on intention-to-treat analyses, for the composite primary end point and the pre-specified secondary end points of total mortality, venous thromboembolism, and incident diabetes.

The 32% of participants in the JUPITER trial who were aged 70 years or older accrued 49% (N=194) of the 393 confirmed primary end points. The rates of the primary end point in this age group were 1.22 and 1.99 per 100 person-years of follow-up in the rosuvastatin and placebo groups, respectively (hazard ratio 0.61; [95% CI, 0.46 to 0.82]; P<0.001). Corresponding rates of secondary end points in this age group were 1.63 and 2.04 for any death (hazard ratio 0.80; [95% CI, 0.62 to 1.04]; P=0.090), 0.24 and 0.41 for venous thromboembolism (hazard ratio 0.58; [95% CI, 0.31 to 1.11] P=0.096), and 1.20 and 0.98 for diabetes (hazard ratio 1.21; [95% CI, 0.86 to 1.71]; P=0.27). Thus, relative effects observed in older participants were quite similar to those reported for the overall trial.

However, because absolute risks were substantially higher in this age group, the estimated number needed to treat (NNT) for 5 years to prevent 1 primary end point was 19, compared with the estimated NNT of 25 for the overall trial.


Discussant | see Presenter abstract

Philippe Gabriel Steg, FESC (France)

Presentation webcast

Presentation slides





Randomized evidence on Rosuvastatin for primary prevention in individuals 70 years of age or older. JUPITER

Notes to editor

This congress report accompanies a presentation given at the ESC Congress 2009. Written by the author himself/herself, this report does not necessarily reflect the opinion of the European Society of Cardiology.

The content of this article reflects the personal opinion of the author/s and is not necessarily the official position of the European Society of Cardiology.